EHA 2018 | MM treatment in the US vs. Europe: multi-drug regimens & cellular therapies

Ola Landgren

Treatments for multiple myeloma (MM) in newly diagnosed and relapsed patients differ between regions, particularly with the rapid advancements in treatment in recent years. Here, Ola Landgren, MD, PhD, from Memorial Sloan Kettering Cancer Center, NY, discusses how MM is treated in the US; highlighting the differences compared with Europe, as a European who now works in the US. Notably, the use of more drugs in combination; namely IMiDs, proteasome inhibitors and steroids, although four-agent regimens with the addition of a monoclonal antibody are in clinical trials. Dr Landgren also discusses the future of MM treatment in the US, with research investigating CAR T-cells, bispecific antibodies and antibody-drug conjugates. This video was recorded at the 23rd congress of European Hematology Association (EHA) 2018, held in Stockholm, Sweden.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter